Description: Bellerophon Therapeutics LLC, a clinical-stage therapeutics company, focuses on the development of various products for the treatment of cardiopulmonary and cardiac diseases. Its product candidates include INOpulse for the treatment of pulmonary arterial hypertension, as well as to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases; and bioabsorbable cardiac matrix, a medical device for the prevention of congestive heart failure. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics LLC in January 2014. Bellerophon Therapeutics LLC was founded in 2009 and is based in Hampton, New Jersey.
Home Page: bellerophon.com
BLPH Technical Analysis
184 Liberty Corner Road
Warren,
NJ
07059
United States
Phone:
908 574 4770
Officers
| Name | Title |
|---|---|
| Mr. Peter Fernandes M. Pharm | Principal Exec. Officer and Chief Regulatory, Safety & Quality Officer |
| Dr. Parag Suresh Shah | VP of Bus. Operations |
| Mr. Nicholas Laccona | Principal Financial & Accounting Officer and Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0544 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-02-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 20 |